DYN- Dyne Therapeutics, Inc.

Trade Summary

1 month ago, Kerr Douglas, serving as Chief Medical Officer at Dyne Therapeutics, Inc. (DYN), sold 5,035 shares at $22.95 per share, for a total transaction value of $115,545.95. Following this transaction, Kerr Douglas now holds 162,564 shares of DYN.

This sale represents a 3.00% decrease in Kerr Douglas's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Friday, September 4, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, September 8, 2026 at 4:14 PM ET, 4 days after the trade was made.

Dyne Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.